Abstract
Increasing experimental studies indicate the existence of novel molecular targets for cannabinoid ligands and recently it has been suggested that the orphan G-protein coupled receptor, GPR55 can be activated by a range of endogenous, plant and synthetic cannabinoids. However, to date, the most potent ligand identified for GPR55 is the endogenous phospholipid, lysophosphatidylinositol (LPI). GPR55 is thought to link predominantly to G-protein α13, where it promotes Rho-dependent signalling. Additional events downstream of GPR55 include activation of ERK-MAP kinase and Ca2+ release from stores, as well as the induction of a number of transcription factors. Although GPR55 has only a low sequence identity with the CB1 or CB2 cannabinoid receptors, it clearly interacts with certain cannabinoid ligands. However, the nature and scope of these effects are presently unclear and they may be influenced by the assay and cellular background used for their study. This article reviews the current status of GPR55 pharmacology and its putative endogenous ligand, LPI.
Keywords: GPR55, Cannabinoid, Lysophosphatidylinositol
Current Topics in Medicinal Chemistry
Title: GPR55, a Lysophosphatidylinositol Receptor with Cannabinoid Sensitivity?
Volume: 10 Issue: 8
Author(s): Tapio Nevalainen and Andrew J. Irving
Affiliation:
Keywords: GPR55, Cannabinoid, Lysophosphatidylinositol
Abstract: Increasing experimental studies indicate the existence of novel molecular targets for cannabinoid ligands and recently it has been suggested that the orphan G-protein coupled receptor, GPR55 can be activated by a range of endogenous, plant and synthetic cannabinoids. However, to date, the most potent ligand identified for GPR55 is the endogenous phospholipid, lysophosphatidylinositol (LPI). GPR55 is thought to link predominantly to G-protein α13, where it promotes Rho-dependent signalling. Additional events downstream of GPR55 include activation of ERK-MAP kinase and Ca2+ release from stores, as well as the induction of a number of transcription factors. Although GPR55 has only a low sequence identity with the CB1 or CB2 cannabinoid receptors, it clearly interacts with certain cannabinoid ligands. However, the nature and scope of these effects are presently unclear and they may be influenced by the assay and cellular background used for their study. This article reviews the current status of GPR55 pharmacology and its putative endogenous ligand, LPI.
Export Options
About this article
Cite this article as:
Nevalainen Tapio and J. Irving Andrew, GPR55, a Lysophosphatidylinositol Receptor with Cannabinoid Sensitivity?, Current Topics in Medicinal Chemistry 2010; 10 (8) . https://dx.doi.org/10.2174/156802610791164229
DOI https://dx.doi.org/10.2174/156802610791164229 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets The Metabolism of Anthocyanins
Current Drug Metabolism Editorial [Hot Topic: Targeted Alpha Therapy – Part II (Guest Editor: Jorgen Elgqvist)]
Current Radiopharmaceuticals Remyelination in Multiple Sclerosis: The Therapeutic Potential of Neural and Mesenchymal Stem/Progenitor Cells
Current Signal Transduction Therapy Production of Retroviral Vectors: Review
Current Gene Therapy In Vitro High Throughput Phage Display Selection of Ovarian Cancer Avid Phage Clones for Near-Infrared Optical Imaging
Combinatorial Chemistry & High Throughput Screening Melatonin Receptor as a Drug Target for Neuroprotection
Current Molecular Pharmacology T Cell Suicide Gene Therapy to Aid Haematopoietic Stem Cell Transplantation
Current Gene Therapy The Design of Amphiphilic Polymeric Micelles of Curcumin for Cancer Management
Current Medicinal Chemistry Discovery of Hedgehog Antagonists for Cancer Therapy
Current Medicinal Chemistry Positron Emission Tomography Imaging of Tumor Hypoxia
Current Medical Imaging Opioid Receptor Interacting Proteins and the Control of Opioid Signaling
Current Pharmaceutical Design Recent Innovations in Antibody-Mediated, Targeted Particulate Nanotechnology and Implications for Advanced Visualisation and Drug Delivery
Current Nanoscience Fusogenic Oncolytic Herpes Simplex Viruses as a Potent and Personalized Cancer Vaccine
Current Pharmaceutical Biotechnology The Function of LncRNA FTX in Several Common Cancers
Current Pharmaceutical Design Sonic Hedgehog Pathway as a Target for Therapy in Angiogenesis-Related Diseases
Current Signal Transduction Therapy A Review on Recent Developments in the Anticancer Potential of Oleanolic Acid and its Analogs (2017-2020)
Mini-Reviews in Medicinal Chemistry Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design Critical Role of IL-8 Targeting in Gliomas
Current Medicinal Chemistry Preparation, Characterization and Drug Release of Salicylic Acid Loaded Porous Electrospun Nanofibers
Recent Patents on Nanotechnology